Quiz: Why isn’t SGP’s TRA antiplatelet drug on the list, given that Fred Hassan has stated on numerous occasions that the phase-3 clinical program for TRA is too expensive for SGP to pursue on its own?
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”